Erdener Ozer MD,PhDDivision Chief of Anatomical Pathology Years Of Experience: 26
- Anatomical Pathology | Molecular Pathology | Pediatric Pathology
About the Physician
Dr. Erdener Ozer is the new Division Chief of Anatomical Pathology, having joined Sidra Medicine in 2021. He is also a senior attending physician managing digital pathology reporting service.
Prior to joining Sidra, Dr. Ozer worked at Dokuz Eylul University Hospital in Turkey as a consultant. He has also held full time professor positions in the School of Medicine where he taught medical students, and in the Institute of Health Sciences, where he supervised PhD candidates.
In addition to his extensive academic experience in anatomical pathology, Dr. Ozer has a PhD degree in Medical Biology& Genetics. His special interest in genomic pathology of pediatric tumors include neuroblastoma, medulloblastoma and Langerhans cell histiocytosis. In his previous role, he was one of the leaders of pediatric oncology group establishing the national treatment protocol of neuroblastoma.
English, German, Turkish26
- BSc in Medicine, Ege University School of Medicine, Turkey
- Speciality Training in Pathology, Dokuz Eylul University School of Medicine, Turkey
- Visiting Fellowship in Paediatric Pathology, Edinburgh Royal Hospital for Sick Children Hospital, UK
- PhD in Medical Biology and Genetics, Dokuz Eylul University, Institute of Health Sciences, Turkey
- Dokuz Eylul University School of Medicine in Turkey
- Paediatric Pathology Society
- Society for Pediatric Pathology
- European Society of Pathology
- European Society of Paediatric Oncology
- International Academy of Pathology
- Pediatric and Perinatal Pathology, Neuropathology, Genomic Pathology, Computational Pathology
- Pediatric Pathology, Neuropathology, Molecular Pathology
- Senfter D, Erkan EP, Ozer E, et al. Overexpression of minichromosome maintenance protein 10 in medulloblastoma and its clinical implications. Ped Blood Cancer 2017; 64: e26670.
- Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: A significant biomarker for prediction of disease relapse in pediatric Langerhans cell histiocytosis. Pediatr Dev Pathol. 2019; 22: 449-455.
- Gul G, Ince D, Olgun N, Ozer E. PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance? Fetal Pediatr Pathol. 2020; 13:1-9.
- Kanit N, Uysal Yoca O, Ince D, Olgun N, Ozer E. Gene-Specific DNA Methylation Profiles in Pediatric Medulloblastomas. Pediatr Dev Pathol [Epub ahead of print].
- Gulen G, Ceyhan M, Ince D, Olgun N, Ozer E. Profile of Selected Antitumor Immune Response Genes in Pediatric Classical Hodgkin Lymphoma. Applied Immunohistochem Mol Morphol [Epub ahead of print].